Psoriasis, a chronic autoimmune skin disorder, affects an estimated 60 million people worldwide, with prevalence varying by region. In Western Europe, the prevalence rate is around 2.5 percent, while in some Northern European countries, it can reach 10 percent. The condition can manifest at any age, with the most common ages of onset being between 20-30 and 50-60 years. Both men and women are affected, though it's more prevalent among non-Hispanic whites.
Psoriasis is characterized by the rapid multiplication and shedding of skin cells, resulting in red, scaly patches often found on elbows, knees and other body parts. Beyond its physical symptoms, psoriasis is associated with serious comorbidities, including psoriatic arthritis, cardiovascular issues and mental health challenges, making comprehensive care essential.
Psoriasis’s complexity necessitates a range of treatments tailored to individual needs. Options for treatment of plaque psoriasis include topical corticosteroids and vitamin D analogues such as for mild cases, while moderate to severe plaque psoriasis can require phototherapy, conventional oral medications, or systemic biologics. Recent approvals by the European Medicines Agency (EMA) such as Sotyktu® (deucravacitinib), a TYK2 inhibitor, offer novel mechanisms of action, and new approaches for treatment.
While challenges remain in the management of plaque psoriasis, the evolving landscape brings optimism for enhanced outcomes and an improved quality of life for individuals living with this chronic skin condition.
To learn more about the intricate landscape of plaque psoriasis treatment, where science and innovation converge to pave the way for a brighter future for patients, we invite you to explore our clinical bulletin by clicking here.